The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction

The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devasta...

Full description

Saved in:
Bibliographic Details
Published inJACC. Cardiovascular interventions Vol. 12; no. 13; pp. 1240 - 1252
Main Authors Khan, Jaffar M, Greenbaum, Adam B, Babaliaros, Vasilis C, Rogers, Toby, Eng, Marvin H, Paone, Gaetano, Leshnower, Bradley G, Reisman, Mark, Satler, Lowell, Waksman, Ron, Chen, Marcus Y, Stine, Annette M, Tian, Xin, Dvir, Danny, Lederman, Robert J
Format Journal Article
LanguageEnglish
Published United States 08.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Dr. Rogers has served as a consultant for Medtronic; and a physician proctor for Edwaids Lifesdences and Medtronic. Drs. Eng and Paone have served as proctors for Edwaids Lifesdences. Dr. Leshnower has served on the Medtronic Speakers Bureau. Dr. Waksman has served on the advisory board for Abbott Vasculai, Amgen, Boston Sdentific, Caidioset, Caidiovasculai Systems, Medtronic, Philips Volcano, and Pi-Cardia; has served as a consultant for Abbott Vasculai, Amgen, Boston Sdentific, Biotronik, Biosensors, Cardioset, Cardiovascular Systems, Philips Volcano, Pi-Cardia, and Medtronic; has received grant support from Abbott Vascular, AstraZeneca, Boston Sdentific, and Chiesi; has served on the Speakers Bureau for AstraZeneca and Chiesi; and is an investor in MedAlliance. Dr. Dvir has served as a consultant for Edwards Lifesdences, Medtronic, and Abbott Vascular. Drs. Khan, Rogers, and Lederman aie co-inventois on patents, assigned to the National Institutes of Health, on cathetei devices to lacerate valve leaflets. All other authors have reported that they have no relationships relevant to the contents of this paper to disdose. Lais Soendergaard, MD, served as the Guest Editor for this paper.
ISSN:1876-7605
1936-8798
1876-7605
DOI:10.1016/j.jcin.2019.03.035